Abstract
As one of the leading causes of deaths worldwide, cancer is posing threat despite efforts being taken to develop effective anticancer drugs. There is an increase in number of chemotherapy treatments due to growing number of manifestations causing increasing toxicities of cytotoxic agents. Almost all the anticancer agents available till date have one or the other side effects. Topoisomerases are the attractive targets to develop effective anticancer agents. There has been development of many topoisomerase inhibitors till date and has shown good anticancer activity but their side effects outnumber their anticancer potential. Hence, there is an urgent need to develop effective therapeutic agents with fewer side effects. This review deals with design and development aspect of topoisomerase inhibitors as exciting novel anticancer agents. The emphasis has been laid in particular on the new potential heterocyles as TOP inhibitors in the field of medicinal chemistry. The review discusses about the topoisomerase poisons, TOP1 suppressors, TOP inhibitors and Dual TOP 1/2 inhibitors.
Keywords: Anticancer, topoisomerase types and inhibitors, structure activity relationship, topoisomerase inhibitors.
Mini-Reviews in Medicinal Chemistry
Title:Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Volume: 16 Issue: 15
Author(s): Muthu K. Kathiravan, Anuj N. Kale and Shrikant Nilewar
Affiliation:
Keywords: Anticancer, topoisomerase types and inhibitors, structure activity relationship, topoisomerase inhibitors.
Abstract: As one of the leading causes of deaths worldwide, cancer is posing threat despite efforts being taken to develop effective anticancer drugs. There is an increase in number of chemotherapy treatments due to growing number of manifestations causing increasing toxicities of cytotoxic agents. Almost all the anticancer agents available till date have one or the other side effects. Topoisomerases are the attractive targets to develop effective anticancer agents. There has been development of many topoisomerase inhibitors till date and has shown good anticancer activity but their side effects outnumber their anticancer potential. Hence, there is an urgent need to develop effective therapeutic agents with fewer side effects. This review deals with design and development aspect of topoisomerase inhibitors as exciting novel anticancer agents. The emphasis has been laid in particular on the new potential heterocyles as TOP inhibitors in the field of medicinal chemistry. The review discusses about the topoisomerase poisons, TOP1 suppressors, TOP inhibitors and Dual TOP 1/2 inhibitors.
Export Options
About this article
Cite this article as:
Kathiravan K. Muthu, Kale N. Anuj and Nilewar Shrikant, Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents, Mini-Reviews in Medicinal Chemistry 2016; 16 (15) . https://dx.doi.org/10.2174/1389557516666160822110819
DOI https://dx.doi.org/10.2174/1389557516666160822110819 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Classification of Heart Disease Using MFO Based Neural Network on MRI Images
Current Medical Imaging Angiotensin II and the Cardiac Complications of Diabetes Mellitus
Current Pharmaceutical Design Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews The Evolving Therapy of Rheumatic Diseases, The Future is Now
Current Drug Targets - Immune, Endocrine & Metabolic Disorders PET Measurements of cAMP-Mediated Phosphodiesterase-4 with (R)-[11C]Rolipram
Current Radiopharmaceuticals Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease
Current Drug Targets Adult Stem Cell Therapy for Cardiac Repair in Patients After Acute Myocardial Infarction Leading to Ischemic Heart Failure: An Overview of Evidence from the Recent Clinical Trials
Current Cardiology Reviews Metabolic Syndrome and Myocardial Infarction in Women
Current Pharmaceutical Design Antioxidant Therapy in Diabetic Complications: What is New?
Current Vascular Pharmacology MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Mechanical Circulatory Support for End-Stage Heart Failure in Repaired and Palliated Congenital Heart Disease
Current Cardiology Reviews Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Role of AMPK in Diabetic Cardiovascular Complications: An Overview
Cardiovascular & Hematological Disorders-Drug Targets Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy Alteration of the Beta-Adrenergic Signaling Pathway in Human Heart Failure
Current Pharmaceutical Biotechnology Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease
Reviews on Recent Clinical Trials